Promyelocytic leukemia-nuclear body proteins: Herpesvirus enemies, accomplices, or both?

Future Virology

Volumn 3, Issue 3, 2008, Pages 265-277

  Saffert, Ryan T ^a   Kalejta, Robert F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

HCMV; HSV 1; Intrinsic immunity; PML NB

Indexed keywords

CELL PROTEIN; DAXX PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMEDIATE EARLY PROTEIN; NUCLEAR PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN VP16; UBIQUITIN PROTEIN LIGASE; VIRUS PROTEIN;

CELL NUCLEUS INCLUSION BODY; CELL TYPE; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOFLUORESCENCE MICROSCOPY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS LATENCY; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 1;

EID: 44149083798     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.3.265     Document Type: Review

References (124)

1. Bieniasz PD: Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5, 1109-1115 (2004).
2. Saffert RT, Kalejta RF: Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. J. Virol. 80, 3863-3871 (2006).
3. Tavalai N, Papior P, Rechter S, Leis M, Stamminger T: Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80, 8006-8018 (2006).
4. Tavalai N, Papior P. Rechter S, Stamminger T: Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. J. Virol. 82, 126-137 (2008).
5. Ishov AM, Sotnikov AG. Negorev D et al.: PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147, 221-234 (1999).
6. Ascoli CA, Maul GG: Identification of a novel nuclear domain. J. Cell Biol. 112, 785-795 (1991).
7. Pellett P. Roizman B: The family Herpesviridae: a brief introduction. In: Fields Virology (2). Knipe DM, Howley PM (Eds)., Lippincott Williams and Wilkins, Philadelphia, PA, USA. p. 2479-2500 (2007).
8. de Bruyn Kops A, Knipe DM: Preexisting nuclear architecture defines the intranuclear location of herpesvirus DNA replication structures. J. Virol. 68, 3512-3526 (1994).
9. Ishov AM, Maul GG: The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. J. Cell Biol. 134, 815-826 (1996).
10. Maul GG, Ishov AM, Everett RD: Nuclear domain 10 as preexisting potential replication start sites of herpes simplex virus type-1. Virology 217, 67-75 (1996).
11. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76, 333-343 (1994).
12. Zhong S, Salomoni P, Pandolfi PP: The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2, E85-E90 (2000).
13. Michaelson JS: The Daxx enigma. Apoptasis 5, 217-220 (2000).
14. Salomoni P. Khelifi AF: Daxx: death or survival protein? Trends Cell Biol. 16, 97-104 (2006).
15. Wang ZG, Ruggero D, Ronchetti S et al.: PML is essential for multiple apoptotic pathways. Nat. Genet. 20, 266-272 (1998).
16. Salomoni P. Pandolfi PP: The role of PML in tumor suppression. Cell 108, 165-170 (2002).
17. Everett RD, Chelbi-Alix MK: PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89, 819-830 (2007).
18. Bernardi R, Pandolfi PP: Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev Mol. Cell Biol. 8, 1006-1016 (2007).
19. Ching RW, Dellaire G, Eskiw CH, Bazett-Jones DP: PML bodies: a meeting place for genomic loci? J. Cell Sci. 118, 847-854 (2005).
20. Negorev D, Maul GG: Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20, 7234-7242 (2001).
21. Zimber A, Nguyen QD, Gespach C: Nuclear bodies and compartments: functional roles and cellular signalling in health and disease. Cell Signal. 16, 1085-1104 (2004).
22. Ishov AM, Stenberg RM, Maul GG: Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J. Cell Biol. 138, 5-16 (1997).
23. Everett RD, Murray J, Orr A, Preston CM: Herpes simplex virus type 1 genomes are associated with ND10 nuclear substructures in quiescently infected human fibroblasts. J. Virol. 81, 10991-11004 (2007).
24. Lavau C, Marchio A, Fagioli M et al.: The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 11, 871-876 (1995).
25. Guldner HH, Szostecki C, Grotzinger T, Will H: IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J. Immunol. 149, 4067-4073 (1992).
26. Gongora R, Stephan RP, Zhang Z, Cooper MD: An essential role for Daxx in the inhibition of B lymphopoiesis by type I interferons. J. Immunol. 14, 727-737 (2001).
27. Ahn JH, Hayward GS: The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 71, 4599-4613 (1997).
28. Everett RD, Maul GG: HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13, 5062-5069 (1994).
29. Korioth F. Maul GG, Plachter B, Stamminger T, Frey J: The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp. Cell Res. 229, 155-158 (1996).
30. Everett RD, Murray J: ND10 components relocate to sites associated with herpes simplex virus type 1 nucleoprotein complexes during virus infection. J. Virol. 79, 5078-5089 (2005).
31. Everett RD, Freemont P. Saitoh H et al.: The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72, 6581-6591 (1998).
32. Chelbi-Alix MK, de The H: Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18, 935-941 (1999).
33. Boutell C, Sadis S, Everett RD: Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76, 841-850 (2002).
34. Stow ND, Stow EC: Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J. Gen. Virol. 67(Pt 12), 2571-2585 (1986).
35. Everett R, O'Hare P, O'Rourke D, Barlow P. Orr A: Point mutations in the herpes simplex virus type 1 Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML-containing nuclear structures. J. Virol. 69, 7339-7344 (1995).
36. Bresnahan WA, Shenk TE: UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells. Proc. Natl Acad Sci. USA 97, 14506-14511 (2000).
37. Cantrell SR, Bresnahan WA: Interaction between the human cytomegalovirus UL82 gene product (pp71) and hDaxx regulates immediate-early gene expression and viral replication. J. Virology 79, 7792-7802 (2005).
38. Hwang J, Kalejta RF: Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells. Virology 367, 334-338 (2007).
39. Cantrell SR, Bresnahan WA: Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication. J. Virol. 80, 6188-6191 (2006).
40. Preston CM, Nicholl MJ: Role of the cellular protein hDaxx in human cytomegalovirus immediate-early gene expression. J. Gen. Virol. 87, 1113-1121 (2006).
41. Liu B, Stinski MF: Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. J. Virol. 66, 4434-4444 (1992).
42. Hofmann H, Sindre H, Stamminger T: Functional interaction between the pp71 protein of human cytomegalovirus and the PML-interacting protein human Daxx. J. Virol. 76, 5769-5783 (2002).
43. Lee HR, Kim DJ, Lee JM et al.: Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 78, 6527-6542 (2004).
44. Muller S, Dejean A: Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73, 5137-5143 (1999).
45. Woodhall DL, Groves IJ, Reeves MB. Wilkinson G, Sinclair JH: Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. J. Biol. Chem. 281, 37652-37660 (2006).
46. Negorev DG, Vladimirova OV, Ivanov A, Rauscher F 3rd, Maul GG: Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression. J. Virol. 80, 8019-8029 (2006).
47. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A: PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICPO. J. Virol. 80, 7995-8005 (2006).
48. Everett RD, Parada C, Gripon P, Sirma H, Orr A: Replication of ICP0 null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82(6), 2661-2672 (2008).
49. Chee AV, Lopez P, Pandolfi PP, Roizman B: Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects. J. Virol. 77, 7101-7105 (2003).
50. Lopez P, Jacob RJ, Roizman B: Overexpression of promyelocytic leukemia protein precludes the dispersal of ND10 structures and has no effeet on accumulation of infectious herpes simplex virus 1 or its proteins. J. Virol. 76, 9355-9367 (2002).
51. Nevels M, Paulus C, Shenk T: Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc. Natl Acad. Sci. USA 101, 17234-17239 (2004).
52. Preston CM, McFarlane M: Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16. Virology 249, 418-426 (1998).
53. Poon AP, Liang Y, Roizman B: Herpes simplex virus 1 gene expression is accelerated by inhibitors of histone deacetylases in rabbit skin cells infected with a mutant carrying a cDNA copy of the infected-cell protein no. 0. J. Virol. 77, 12671-12678 (2003).
54. Terry-Allison T, Smith CA. DeLuca NA: Relaxed repression of herpes simplex virus type 1 genomes in murine trigeminal neurons. J. Virol. 81, 12394-12405 (2007).
55. Arthur JL, Scarpini CG, Connor V, Lachmann RH, Tolkovsky AM, Efstathiou S: Herpes simplex virus type 1 promoter activity during latency establishment, maintenance, and reactivation in primary dorsal root neurons in vitro. J. Virol. 75, 3885-3895 (2001).
56. Danaher RJ, Jacob RJ, Steiner MR, Allen WR, Hill JM, Miller CS: Histone deacetylase inhibitors induce reactivation of herpes simplex virus type 1 in a latency-associated transcript-independent manner in neuronal cells. J. Neurovirol. 11, 306-317 (2005).
57. Lomonte P, Thomas J, Texier P, Caron C, Khochbin S, Epstein AL: Functional interaction between class II histone deacetylases and ICPO of herpes simplex virus type 1. J. Virol. 78, 6744-6757 (2004).
58. Gu H, Roizman B: Herpes simplex virus-infected cell protein 0 blocks the silencing of viral DNA by dissociating histone deacetylases from the CoREST-REST complex. Proc. Natl Acad. Sci. USA 104, 17134-17139 (2007).
59. Gu H, Liang Y, Mandel G. Roizman B: Components of the REST/CoREST/ histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells. Proc. Natl Acad. Sci. USA 102, 7571-7576 (2005).
60. Coleman HM, Connor V, Cheng ZS, Grey F, Preston CM, Efstathiou S: Histone modifications associated with herpes simplex virus type 1 genomes during quiescence and following ICP0-mediated de-repression. J. Gen. Virol. 89, 68-77 (2008).
61. Triezenberg SJ: Structure and function of transcriptional activation domains. Curr. Opin. Genet. Dev. 5, 190-196 (1995).
62. Wysocka J, Herr W: The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem. Sci. 28, 294-304 (2003).
63. Flint J, Shenk T: Viral transactivating proteins. Annu. Rev. Genet. 31, 177-212 (1997).
64. Rotzman B, Knipe DM, Whitley RJ: Herpes simplex viruses. In: Fields Virology (2). Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, Philadelphia, PA, USA, p. 2501-2602 (2007).
65. Herrera FJ, Triezenberg SJ: VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection. J. Virol. 78, 9689-9696 (2004).
66. Gu B, DeLuca N: Requirements for activation of the herpes simplex virus glycoprotein C promoter in vitro by the viral regulatory protein ICP4. J. Virol. 68, 7953-7965 (1994).
67. Grondin B, DeLuca N: Herpes simplex virus type 1 ICP4 promotes transcription preinitiation complex formation by enhancing the binding of TFIID to DNA. J. Virol. 74, 11504-11510 (2000).
68. Carrozza MJ, DeLuca NA: Interaction of the viral activator protein ICP4 with TFIID through TAF250. Mol. Cell Biol. 16. 3085-3093 (1996).
69. Sampath P, Deluca NA: Binding of ICP4, TATA-binding protein, and RNA polymerase II to herpes simplex virus, type 1 immediate early, early and late promoters in virus-infected cells. J. Virol. 82(5), 2339-2349 (2008).
70. Roberts MS, Boundy A, O'Hare P, Pizzorno MC, Ciufo DM, Hayward GS: Direct correlation between a negative autoregulatory response element at the cap site of the herpes simplex virus type 1 IE175 (alpha 4) promoter and a specific binding site for the IE175 (ICP4) protein. J. Virol. 62, 4307-4320 (1988).
71. Michael N, Roizman B: Repression of the herpes simplex virus 1 alpha 4 gene by its gene product occurs within the context of the viral genome and is associated with all three identified cognate sites. Proc. Natl Acad. Sci USA 90, 2286-2290 (1993).
72. Leopardi R, Michael N, Roizman B: Repression of the herpes simplex virus 1 alpha 4 gene by its gene product (ICP4) within the context of the viral genome is conditioned by the distance and steroaxial alignment of the ICP4 DNA binding site relative to the TATA box. J. Virol. 69, 3042-3048 (1995).
73. Castillo JP, Kowalik TF: Human cytomegalovirus immediate early proteins and cell growth control. Gene 290, 19-34 (2002).
74. Mocarski ES, Shenk T, Pass RF: Cytomegaloviruses. In: Fields Virology. Knipe DM, Howley PM (Eds)., Lippincott Williams and Wilkins. Philadelphia, PA, USA, p. 2701-2772 (2007).
75. Park JJ, Kim YE, Pham HT, Kim ET, Chung YH, Ahn JH: Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts. J. Gen. Virol. 88, 3214-3223 (2007).
76. Reeves M, Murphy J, Greaves R, Fairley J, Brehm A, Sinclair J: Autorepression of the human cytomegalovirus major immediate-early promoter/enhancer at late times of infection is mediated by the recruitment of chromatin remodeling enzymes by IE86. J. Virol. 80, 9998-10009 (2006).
77. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH: Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72(Pt 9). 2059-2064 (1991).
78. Taylor-Wiedeman J, Sissons P, Sinclair J: Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J. Virol. 68, 1597-1604 (1994).
79. Hahn G, Jores R, Mocarski ES: Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl Acad. Sci. USA 95, 3937-3942 (1998).
80. Khalboullina SF, Maciejewski JP, Crapnell K et al.: Human cytomegalovirus persists in myeloid progenitors and is passed to the myeloid progeny in a latent form. Br. J. Haematol. 126, 410-417 (2004).
81. Goodrum F, Reeves M, Sinclair J, High K, Shenk T: Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110, 937-945 (2007).
82. Goodrum FD, Jordan CT, High K, Shenk T: Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc. Natl Acad. Sci. USA 99, 16255-16260 (2002).
83. Reeves MB, Lehner PJ, Sissons JG, Sinclair JH: An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J. Gen. Virol. 86, 2949-2954 (2005).
84. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH: Latency. chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl Acad. Sci. USA 102, 4140-4145 (2005).
85. Cheung AK, Abendroth A, Cunningham AL, Slobedman B: Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood 108, 3691-3699 (2006).
86. Sinclair J, Sissons P: Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 87, 1763-1779 (2006).
87. Murphy JC, Fischle W, Verdin E, Sinclair JH: Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 21, 1112-1120 (2002).
88. Ioudinkova E, Arcangeletti MC, Rynditch A et al.: Control of human cytomegalovirus gene expression by differential histone modifications during lytic and latent infection of a monocytic cell line. Gene 384, 120-128 (2006).
89. Keller MJ, Wu AW, Andrews JI, McGonagill PW, Tibesar EE, Meier JL: Reversal of human cytomegalovirus major immediate-early enhancer/ promoter silencing in quiescently infected cells via the cyclic-AMP signaling pathway. J. Virol.. 81, 6669-6681 (2007).
90. Meier JL: Reactivation of the human cytomegalovirus major immediate-early regulatory region and viral replication in embryonal NTera2 cells: role of trichostatin A, retinoic acid, and deletion of the 21-base-pair repeats and modulator. J. Virol. 75, 1581-1593 (2001).
91. Yee LF, Lin PL, Stinski MF: Ectopic expression of HCMV IE72 and IE86 proteins is sufficient to induce early gene expression but not production of infectious virus in undifferentiated promonocytic THP-1 cells. Virology, 363, 174-188 (2007).
92. Saffert RT, Kalejta RF: Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. J. Virol. 81, 9109-9120 (2007).
93. Meier JL, Stinski MF: Regulation of human cytomegalovirus immediate-early gene expression. Intervirology 39: 331-342 (1996).
94. Groves IJ, Sinclair JH: Knockdown of hDaxx in normally non-permissive undifferentiated cells does not permit human cytomegalovirus immediate-early gene expression. J. Gen. Virol. 88. 2935-2940 (2007).
95. La Boissiere S, Hughes T, O'Hare P: HCF-dependent nuclear import of VP16. EMBO J. 18, 480-489 (1999).
96. Kristie TM, Vogel JL, Sears AE: Nuclear localization of the C1 factor (host cell factor) in sensory neurons correlates with reactivation of herpes simplex virus from latency. Proc. Natl Acad. Sci. USA 96, 1229-1233 (1999).
97. Sears AE, Hukkanen V, Labow MA, Levine AJ, Roizman B. Expression of the herpes simplex virus 1 alpha transinducing factor (VP16) does not induce reactivation of latent virus or prevent the establishment of latency in mice. J. Virol. 65, 2929-2935 (1991).
98. Samaniego LA, Neiderhiser L, DeLuca NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72, 3307-3320 (1998).
99. Preston CM, Nicholl MJ: Human cytomegalovirus tegument protein pp71 directs long-term gene expression from quiescent herpes simplex virus genomes. J. Virus. 79, 525-535 (2005).
100. Minaker RL, Mossman KL, Smiley JR: Functional inaccessibility of quiescent herpes simplex virus genomes. Virol. J. 2, 85 (2005).
101. Hobbs WE, Brough DE, Kovesdi I, DeLuca NA: Efficient activation of viral genomes by levels of herpes simplex virus ICPO insufficient to affect cellular gene expression or cell survival. J. Virol. 75, 3391-3403 (2001).
102. Chen SH, Lee LY, Garber DA, Schaffer PA, Knipe DM, Coen DM: Neither LAT nor open reading frame P mutations increase expression of spliced or intron-containing ICPO transcripts in mouse ganglia latently infected with herpes simplex virus. J. Virol. 76, 4764-4772 (2002).
103. Maillet S, Naas T, Crepin S et al.: Herpes simplex virus type 1 latently infected neurons differentially express latency-associated and ICPO transcripts. J. Virol. 80, 9310-9321 (2006).
104. Mador N, Goldenberg D, Cohen O, Panet A, Steiner I: Herpes simplex virus type 1 latency-associated transcripts suppress viral replication and reduce immediate-early gene mRNA levels in a neuronal cell line. J. Virol. 72, 5067-5075 (1998).
105. Thompson RL, Shieh MT. Sawtell NM: Analysis of herpes simplex virus ICPO promoter function in sensory neurons during acute infection, establishment of latency, and reactivation in vivo. J. Virol. 77, 12319-12330 (2003).
106. Bego M, Maciejewski J, Khaiboullina S. Pari G, St Jeor S: Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J. Virol. 79, 11022-11034 (2005).
107. Knipe DM, Cliffe A: Chromatin control of herpes simplex virus lytic and latent infection. Nat. Rev. Microbiol. 6, 211-221 (2008).
108. Adamson AL, Kenney S: Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol. 75, 2388-2399 (2001).
109. Stanton R, Fox JD, Caswell R, Sherratt E. Wilkinson GW: Analysis of the human herpesvirus-6 immediate-early 1 protein. J Gen. Virol. 83, 2811-2820 (2002).
110. Hoppe A, Beech SJ, Dimmock J, Leppard KN: Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J. Virol. 80, 3042-3049 (2006).
111. Ullman AJ, Reich NC, Hearing P: Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response. J. Virol, 81, 4744-4752 (2007).
112. Guccione E. Lethbridge KJ,. Killick N, Leppard KN, Banks L: HPV E6 proteins Interact with specific PML isoforniAlmd allow distinctions to be made between different POD structures. Oncogene 23. 4662-4672 (2004).
113. Bischof O, Nacerddine K, Dejean A: Human papillomavirus oncoprotein E7 targets the promyelocytic leukemia protein and circumvents cellular senescence via the Rb and p53 tumor suppressor pathways. Mol. Cell Blol. 25, 1013-1024 (2005).
114. Florin L, Schafer F, Sotlar K, Streack RE, Sapp M: Reorganization of nuclear domain 10 induced by papillornavirus capsid protein 12. Virology 295, 97-107 (2002).
115. Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, Chelbi-Alix MK: PML mediates the interferon-induced anti viral state against a complex retrovirus via its association with the viral transactivator. EMBO J. 20, 3495- 3505 (2001).
116. Greger JG, Katz RA, Ishov AM, Maul GG, Skalka AM: ne cellular protein Daxx interacts with avian sarcoma virus Integrase and viral DNA to repress viral transcription. J. Virol. 79, 4610-4618 (2005).
117. Poleshko A, Palagin I, Zhang R et al.: Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response. J. Virol. 82(5), 2313-2323 (2007).
118. Chelbi-Anx MK, Quignon F, Pelicano L, Koken MH, de The H: Resistance to virus infection conferred by the interferoninduced promyelocytic leukemia protein. J Virol. 72. 1043-1051 (1998).
119. Bell P, Brazas R, Ganem D, Maul GG: Hepatitis delta virus replication generates complexes of large hepatitis delta antigen and antigenomic RNA that affiliate with and alter nuclear domain 10. J. Virol. 74, 5329-5336 (2000).
120. Brasier AR, Spratt H, Wu Z et al.: Nuclear heat shock response and novel nuclear domain 10 reorganization in respiratory syncytial virus-infected a549 cells identified by high-resolution two-dimensional gel electrophoresis. J. Virol. 78, 11461-11476 (2004).
121. Li XD, Makela TP, Guo D et al.: Hantavirus nucleocapsid protein interacts with the Fas-mediated apbptosis enhancer Daxx. J Gen. Virol. 83. 759-766 (2002).
122. Limjindaporn T. Netsawang J, Noisakran S et al.: Sensitization to Fas-mediated apoptosis by dengue virus capsid protein. Biochem. Biophys. Res. Commun. 362, 334-339 (2007).
123. Herzer K, Weyer S, Krammer PH, Galle PR. Hofmann TG: Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res. 65, 10830-10837 (2005).
124. Chen JZ, Ji CN, Xu GL et al.: Daxx interacts with phage Ph1C31 integrase and inhibits recombination. Nucleic Acids Res. 34, 6298-6304 (2006).